Modulators of vasopressin receptors with therapeutic potential

Abstract

Compounds comprising piperazines, piperidines, spiro-furanopiperidines, and analogs thereof are provided that are modulators, such as positive allosteric modulators, of one or more subclasses of vasopressin receptors. The compounds can be selective modulators of one or more subclasses of vasopressin receptors. Compounds of the invention can be used in the treatment of a condition wherein modulating a vasopressin receptor is medically indicated for treatment of the condition.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application No. 61 / 765,956, filed February 18, 2013, and U.S. Provisional Application No. 61 / 765,968, filed February 18, 2013, the disclosures of which are incorporated herein by reference in their entirety . [0003] Statement of Government Support [0004] This invention was made with government support under grant number MH082878 awarded by the National Institutes of Health. The US Government has certain rights in this invention. Background of the invention [0005] Arginine vasopressin (AVP) receptors belong to a family of G-protein coupled receptors characterized by seven transmembrane helices. For a recent review of AVP receptors see Jard, 1998; Barberis et al., 1999; Gimpland Fahrenholz, 2001; Holmes et al., 2003, 2004. [0006] AVP is thought to mediate its action through at least three known receptor subtypes (V1A, V1B (or V3) and V2) as well as the putati...

AI Technical Summary

Problems solved by technology

However, with the exception of the V1A antagonist SRX-251 (Ferris et al., 2006; Guillo

Images